Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive ...

BOSTON & MONTREAL, June 25, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food ...

Additionally, multivariable analyses demonstrated that detectable ctDNA before radical cystectomy was associated with a higher risk of nodal disease (OR 5.4, 95% CI 1.9-18.2; p = 0.003) and locally ...

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

A new study published in the British Journal of Urology International found that sarcopenia was linked to increased the risk ...

DelveInsight's, “Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ ...

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder ...

Nhungo, C.J., Nyongole, O.V. and Mkony, C.A. (2025) Radical Cystectomy for Bladder Cancer in Sub-Saharan Africa Techniques, Challenges, and Survival Outcomes A Comprehensive Review. BMC Surgery, 25, ...

Around one in 10 women will develop ovarian cysts at some point during their lives, and while the prospect of a cyst growing ...

Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301). Authors : Dickon Hayne , Alison Yan Zhang , Hayley ...